Anne Wojcicki wanted to run things—alone. It was 2009 and her startup 23andMe was riding high, fueled by a steady stream of venture money, intriguing personal accounts of genome exploration, and the ...

Biotech company 23andMe was once hailed as one of the most successful businesses selling DNA analysis services to anybody who could afford one of its saliva test kits. But 18 years after it was ...

What have we learned from the era of special purpose acquisition companies? They emerged quickly during the pandemic, seemingly out of nowhere, when 0 percent interest rates prevailed. Today the ...

Matthew Herper covers medical innovation — both its promise and its perils. 23andMe, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business ...

23andMe co-founder Anne Wojcicki is back at the helm. Wojcicki, who stepped down as 23andMe CEO in March, leads a nonprofit called TTAM — the first letters of 23andMe. TTAM is the new buyer for ...

Regeneron Pharmaceuticals has agreed to acquire nearly all of 23andMe’s assets for $256 million, including its genetic data, following a bankruptcy auction. The deal still needs to be approved by the ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more With all seven independent directors ...

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year. The DNA testing company has faced major ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The cofounder and CEO's latest ...